Information Provided By: 
Fly News Breaks for May 19, 2015
ICPT
May 19, 2015 | 11:57 EDT
As previously reported, BofA/Merrill downgraded Intercept to Neutral from Buy. The firm said with the announcement of Intercept's Phase 3 REGENERATE trial to evaluate OCA for NASH removes a catalyst for shares. BofA/Merrill believes the focus will now turn to PBC approval and expected in 1H 2016 launch, which is reflected in valuation. The firm maintains its $315 price target.
News For ICPT From the Last 2 Days
There are no results for your query ICPT
